Company Filing History:
Years Active: 2021-2024
Title: Inventor Spotlight: Ann-Charlotte Dahlquist
Introduction
Ann-Charlotte Dahlquist, an accomplished inventor based in Lund, Sweden, has made significant contributions to the field of pharmaceuticals. With a total of five patents to her name, her work focuses on innovative formulations and crystal modifications of key pharmaceutical compounds.
Latest Patents
Among her most recent patents are the advancements in crystal modifications of odevixibat. This particular invention details two crystal modifications—specifically, crystal modifications 1 and 2 of 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N—{(R)-α-[N—((S)-1-carboxypropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine (odevixibat). The patent not only encompasses the formulations but also describes a process for the preparation of crystal modification 1, along with its potential pharmaceutical compositions for treating various medical conditions. Additionally, her patent concerning the pharmaceutical formulation of odevixibat emphasizes a pediatric application designed for liver diseases, especially conditions like biliary atresia and progressive familial intrahepatic cholestasis (PFIC).
Career Highlights
Ann-Charlotte has built her career at Albireo AB, where she collaborates with a dedicated team to push the boundaries of pharmaceutical science. Her role has positioned her at the forefront of developing innovative solutions for complex health issues, underscoring her commitment to improving patient outcomes.
Collaborations
During her career, Ann-Charlotte has worked closely with notable colleagues including Robert Lundqvist and Ingvar Ymen. These collaborations foster an environment of innovation, enhancing the development of groundbreaking therapeutic options.
Conclusion
In conclusion, Ann-Charlotte Dahlquist is a pivotal figure in the pharmaceutical industry whose inventions have the potential to change lives. Her contributions, particularly in the realm of odevixibat, highlight her expertise and dedication to advancing medical science. As she continues her work at Albireo AB, we can anticipate further innovations that will significantly impact healthcare.